Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Completed PHASE3 INTERVENTIONAL NCT04224818

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in patients with poor ovarian reserve seeking IVF/ICSI treatment.

Detailed Description

Women with POR (Bologna criteria) manifest a very low follicular response to controlled ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of oocyte maturation was shown to improve follicle collection yield and oocyte maturation in women with predicted normal ovarian response. These benefits have been attributed to the GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion. The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for final oocyte maturation improve oocyte collection and maturation rate

Interventions

Name: Dual trigger
Type: DRUG
Description: Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
Name: hCG (standard)
Type: DRUG
Description: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)

Primary Outcomes

Measure: Number of oocytes retrieved (oocyte collection rate)
TimeFrame: 38 hrs
Description: the total number of oocytes retrieved divided by the number of follicles aspirated (diameter ≥10 mm) on the day of oocyte retrieval
Measure: Number of mature oocytes (oocyte maturation rate)
TimeFrame: 38 hrs
Description: the ratio of MII oocytes to the number of collected oocytes

Trial Information

NCT ID

NCT04224818

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

American University of Beirut Medical Center

Last Updated

December 15, 2025